Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
C1 esterase inhibitor
|
| gptkbp:amends |
may be needed in renal impairment
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Ruconest
|
| gptkbp:clinicalTrials |
Phase III trials
improved quality of life for patients emergency treatment as needed for acute attacks included in angioedema management guidelines recommended for acute treatment reduces attack severity showed significant improvement in symptoms use in acute settings only |
| gptkbp:community_service |
assistance programs available
available for patients |
| gptkbp:contraindication |
hypersensitivity reactions
known hypersensitivity to the product |
| gptkbp:customerFeedback |
generally positive
|
| gptkbp:date |
2014-10-24
|
| gptkbp:dosageForm |
individualized based on weight
|
| gptkbp:drugInterdiction |
injectable solution
rapid onset of action limited interactions reported monitored for adverse events |
| gptkbp:educational_programs |
available for healthcare providers
|
| gptkbp:endOfLife |
approximately 2.5 hours
|
| gptkbp:firstAppearance |
in_Europe_in_2013
|
| gptkbp:formulation |
lyophilized powder for reconstitution
|
| gptkbp:hasPopulation |
adults and adolescents
|
| gptkbp:healthcare |
recommended during treatment.
important for safe administration instruct on proper use |
| https://www.w3.org/2000/01/rdf-schema#label |
Ruconest
|
| gptkbp:insuranceAccepted |
varies by plan
|
| gptkbp:is_monitored_by |
monitor for allergic reactions
|
| gptkbp:mandates |
acute attacks of angioedema
|
| gptkbp:manufacturer |
Pharming_Group_N.V.
|
| gptkbp:marketedAs |
multiple countries worldwide
|
| gptkbp:marketSegment |
ongoing monitoring for safety
|
| gptkbp:offers |
varies by region
|
| gptkbp:packaging |
single-use vials
|
| gptkbp:providesSupportFor |
rarely reported
|
| gptkbp:regulatoryCompliance |
approved in multiple jurisdictions
|
| gptkbp:research |
funded_by_Pharming_Group_N.V.
|
| gptkbp:research_areas |
biologic therapy
|
| gptkbp:researchInterest |
ongoing studies for long-term efficacy
|
| gptkbp:route |
intravenous
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:storage |
store at 2°C to 8°C
|
| gptkbp:supplyChain |
managed_by_Pharming_Group_N.V.
|
| gptkbp:triggerType |
replenishes C1 inhibitor levels
|
| gptkbp:usedFor |
treatment of hereditary angioedema
|
| gptkbp:waterManagement |
primarily through the kidneys
|